Company Overview: DBV Technologies S.A.

Company Name: DBV Technologies S.A.
Jurisdiction: France
Address: 107 avenue de la République, 92320 Châtillon, France
Telephone: +33 1 55 42 78 78

Business Focus

DBV Technologies is a biotechnology company specializing in the development of innovative immunotherapies, particularly aimed at allergy and immunology treatment. The company focuses on creating products that utilize medical devices such as patches to deliver desensitization therapies.

Securities

• American Depositary Shares (ADS): Each representing five ordinary shares, with a nominal value of €0.10 per share, traded on The Nasdaq Stock Market LLC under the symbol DBVT.
• Ordinary Shares: Nominal value €0.10, not listed separately apart from the ADS.

Financial and Operational Highlights (as of April 30, 2025)

• Number of Outstanding Shares: 136,948,872 ordinary shares.
• Market Value (as of June 30, 2024): Approximately $84.2 million based on the closing price of ADSs on Nasdaq.
• Employees: Not specified in the provided document.
• Revenue: Not provided.
• Net Income / Loss: Not provided.

Shareholder Structure

• The company has a diverse ownership base including various institutional investors, venture capital funds, and large shareholders, with significant holdings by entities affiliated with Baker Bros. Advisors LP, Bpifrance Participations S.A., Suvretta, Vivo Opportunity Fund, and others.
• No detailed financial data (revenue, income, or number of customers) is given in this specific filing.

Notes

• The company filed an Amendment No. 2 to its annual report (Form 10-K/A) primarily to update beneficial ownership information and the description of registered securities.
• The filing emphasizes ownership disclosures and other legal and regulatory details but does not specify operational metrics, financial results, number of customers, or workforce size beyond ownership data.

Summary:
DBV Technologies S.A. is a French biotechnology firm focused on allergy immunotherapy, leveraging innovative delivery devices such as patches. It is publicly traded on Nasdaq through ADSs, with a significant ownership base of institutional investors and funds. Specific data on revenue, customers, and employees is not provided in the given document.